Current & Future Treatments for Food Allergy (AAN)
Price: FREE for members and non-members
Session recorded on September 27, 2022
Speaker: Akaterina Anagnostou, MD
Description: With multiple novel therapies for food allergy, healthcare providers and patients need to have a better understanding of both risks and benefits of available options, in order to choose accordingly. This presentatio will explore benefits and risks of novel therapies with the intent to improve the management of food allergies.
Viewers can earn credit by completing the posttest questions.
This program is a collaboration between the American College of Allergy, Asthma and Immunology and the Allergy and Asthma Network.
Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Target Audience
Primary Care Providers
Fellows-in-Training
Learning Objectives
Upon completion of this activity learners should be able to:
1. Describe risks and benefits of food oral immunotherapy
2. Discuss epicutaneous and sublingual immunotherpay routes for food allergy
3. Identify the role of the microbiome in food allergy therapy
All relevant finaicial relationships have been mitigated.
Michael Blaiss, MD, FACAAI Planner
Disclosures: Consultant: ALK, DBV, Hycor, Merck, Pfizer, Sanofi, Stallergenes Greer, PMD Healthcare
Akaterini Anagnostou, MD, FACAAI Speaker
Disclosures: Consultant: DBV, ALK; Speaker: Aimmmune; Researcher: Aimmune, Novartis.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance